EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors

Chih-Jie Shen, Joy Florentino-Krasnov, You-Cheng Liao, Hong-Wen Tang, Bahagia Willibrordus Maria Nainggolan, Yung-Hsiao Chiang, Tsung-I Hsu

Cancer Immunology, Immunotherapy · 10.04.2026 · 75 (5)

DOI: 10.1007/s00262-026-04372-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 10.04.2026. Verfasst von Chih-Jie Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: TMU Research Center of Neuroscience, Taipei Medical University, Taipei, 110, Taiwan. Hauptthemen laut MEDLINE: Killer Cells, Natural, Dinoprostone, Brain Neoplasms, Cyclooxygenase 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council of Taiwan, Office of Research and Development, Taipei Medical University, TMU-Ji Yan Biomedical Co., Ltd. Industry-Academia Collaboration Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aggressive brain tumors such as glioblastoma (GBM) remain among the most lethal human cancers, with a median survival of only 15 months despite multimodal treatment. Their resistance arises from a triad of barriers-the blood-brain barrier (BBB), marked intratumoral heterogeneity, and a profoundly immunosuppressive tumor microenvironment (TME). Immunotherapeutic strategies based on natural killer (NK) and T cells, leveraging antigen-independent cytotoxicity and antigen-specific precision, respectively, offer potential breakthroughs but are often limited by chronic neuroinflammation. A key driver of TME suppression is prostaglandin E2 (PGE2), produced via the cyclooxygenase-2 (COX-2) pathway. PGE2 exerts a dual role: Intracellularly, it can promote apoptosis, whereas extracellularly, it fosters tumor progression, immune evasion, and therapeutic resistance. Through activation of EP2 and EP4 receptors, PGE2 signals via Gαs proteins to elevate cyclic adenosine monophosphate (cAMP), leading to impaired cytotoxic immunity. This signaling downregulates NK cell activating receptors (e.g., NKG2D, NKp30), induces CD8⁺ T cell exhaustion, and promotes regulatory T cell expansion. The COX-2/PGE₂ axis further mediates resistance to checkpoint inhibitors, CAR-T therapy, and chemotherapy by enhancing neuronal excitation through EP1 receptor activation in GBM. Targeting this pathway has therefore emerged as a compelling therapeutic strategy, which can restore NK and T cell function and sensitize tumors to immunotherapy. Combining PGE₂ modulation with next-generation NK/T cell approaches-including CAR-NK and CAR-T platforms-holds promise to overcome immune resistance and redefine therapeutic paradigms for GBM and other central nervous system malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalDinoprostoneBrain NeoplasmsCyclooxygenase 2ImmunotherapyT-LymphocytesHumansAnimalsTumor Microenvironment

Stichwörter der Autor:innen

EP2/EP4 receptorsGlioblastomaNK and T cell immunotherapyProstaglandin E2Tumor microenvironment

Substanzen

DinoprostoneCyclooxygenase 2

Autor:innen und Institutionen

  • TMU Research Center of Neuroscience, Taipei Medical University, Taipei, 110, Taiwan.
  • International Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei, 110, Taiwan.
  • Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei, 110, Taiwan.
  • Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, 169857, Singapore.
  • Department of Neurosurgery, Universitas Sumatera Utara, Medan, 20154, North Sumatera, Indonesia.
  • TMU Research Center of Neuroscience, Taipei Medical University, Taipei, 110, Taiwan. ychiang@tmu.edu.tw.

Förderung

  • National Science and Technology Council of Taiwan
  • Office of Research and Development, Taipei Medical University
  • TMU-Ji Yan Biomedical Co., Ltd. Industry-Academia Collaboration Project
  • Sunny Brain Tumor and Brain Disease Research and Development Fund
  • TMU–Ji Yan Biomedical Co., Ltd. Industry–Academia Collaboration Project

Zitieren

APA

Shen, C. J., Florentino-Krasnov, J., Liao, Y. C., Tang, H. W., Nainggolan, B. W. M., Chiang, Y. H., & Hsu, T. I. (2026). Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors. Cancer Immunology, Immunotherapy, 75(5). https://doi.org/10.1007/s00262-026-04372-5

Vancouver

Shen CJ, Florentino-Krasnov J, Liao YC, Tang HW, Nainggolan BWM, Chiang YH, et al. Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors. Cancer Immunology, Immunotherapy. 2026;75(5). doi:10.1007/s00262-026-04372-5

BibTeX
@article{Shen2026,
  author = {Shen, Chih-Jie and Florentino-Krasnov, Joy and Liao, You-Cheng and Tang, Hong-Wen and Nainggolan, Bahagia Willibrordus Maria and Chiang, Yung-Hsiao and Hsu, Tsung-I},
  title = {Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {5},
  doi = {10.1007/s00262-026-04372-5}
}
Kostenlos starten →